Acetonides of 9-halogenated 3beta,11beta,10alpha,17alpha,21-pentahydroxypregnanes



U.S. Cl. 260-23955 10 Claims ABSTRACT OF THE DISCLOSURE The invention disclosed herein teaches new pharmaceutically active compounds having the formulae "lnitedStates Patent Offifie wherein R is hydrogen or acyl; R is hydrogen or acyl; R is hydrogen, acyl or Z-tetrahydropyranyl; the acyl in each instance being a hydrocarbon carboxylic acid of less than twelve carbons; R is hydroxy or acyloxy; R is hydrogen and R and R together are oxo (0:); X is halogen (e.g., chloro or fluoro); P is hydrogen, lower alkyl, halo lower alkyl, carboxy lower alkyl (or a salt or ester thereof), monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl, and Q is lower alkyl, halo lower alkyl, carboxy lower alkyl (or a salt or ester thereof), monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl, or together with the carbon atom to which they are joined P and Q are cycloalkyl or monocyclic heterocyclic; and Z indicates a single ora double bond. These new acetonides possess anti-inflammatory activity and can be prepared by various methods.

3,541,602 Patented Nov. 17, 1970 wherein R' is hydrogen or acyl; R is hydrogen or acyl; R is hydrogen, acyl or Z-tetrahydropyranyl; the acyl in each instance being a hydrocarbon carboxylic acid of less than twelve carbons; R is hydroxy or acyloxy; R is hydrogen and R and R together are oxo (0:); X is halogen (e.g., chloro or fluoro); P is hydrogen, lower alkyl, halo lower alkyl, carboxy lower alkyl (or a salt or ester thereof), monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl, and Q is lower alkyl, halo lower alkyl, carboxy lower alkyl (or a salt or ester thereof), monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl, or together with the carbon atom to which they are joined P and Q are cycloalkyl or monocyclic heterocyclic; and Z indicates a single or a double bond.

The preferred acyl radicals are those of hydrocarbon carboylic acids of less than twleve carbon atoms, as exern plified by the lower alkanoic acids (e.g., acetic, propionic, butyric, and tert-pentanoic acid), the lower alkenoic acids, the monocyclic aryl carboxylic acids (e.g., benzoic and toluic acid), the monocyclic aryl lower alkanoic acids (e.g., phenacetic and fi-phenylpropionic acid), the cycloalkane carboxylic acids and the cycloalkene carboxylic acids.

The final products of this invention possess anti-inflammatory activity. Therefore, they can be employed in lieu of cortisone as anti-inflammatory agents in the treatment of acute inflammatory and allergic diseases of the eye, skin and mucosa. For these purposes, oral dosages may vary from about 0.05 to 1.5 mg./kg. daily, intramuscular dosages from about 0.1 to 4.5 mg./kg. daily, intravenous dosages up to about 1.5 mg./kg. daily (by drip) and topically, they may be administered as an 0.1 to 2.5% suspension, ointment, cream, or the like.

The novel compounds of this invention are prepared by processes disclosed herein which entail various steps starting with 9a-fluoro-16a-hydroxyhydrocortisone 16,17- acetonide, 9a-fluoro-l6ot-hydroxyprednisolone 16,17-acetonide their acylated derivatives and 2l-(2-tetrahydropyranyl) ethers or 3,3-ethylenedioxy-9a-halo-llfl,16m,l7a., 21-tetrahydroxypregna-5-ene-20-one 16,17-acetonide and Zl-acylated as well as 16,17-acetal derivatives.

Preferred end products of this invention are 9a-halo- 318,11B,l6u,17a,21-pentahydroxypregn-4-en-20-one 16,17- acetonide, 9oz halo 3/3,l1B,l6a,17,21 pentahydroxypregna-l,4-diene-20-one 16,17-acetonide and their acylated derivatives, halo 11/3,16u,17u,21-t6t1ahyd1OXypregn 5 ene 3,20 dione 16,17 acetonide, 9a halo- 11fi,16oz,17a,21 tetrahydroxypregna 1,5 diene 3,20- dione 16,17-acetonide their acylated and acetal derivatives and 9c: halo 3fi,llfi,l6oe,17oc,21 pentahydroxypregn- 5-en-20-one l6,l7acetonide, '9a-halo-3,B,1lp,16a,l7u,2lpenahydroxypregna 1,5 diene 20 one 16,17 acetonide and their 2l-acylated derivatives.

The steps of the processes involved in this invention may be represented by the following equations.

products may then be acylated, for example, by treating with acetic anhydride in pyridine or other acylating agents to obtain the corresponding 3,21-diacyl derivatives.

Compounds of the general Formula E can be prepared by either of two routes. One method involves reaction of 9a-halo-16a-hydroxyhydrocortisone 16,17-acetonide 21- (2-tetrahydropyranyl) ether or the l-dehydro derivative With a base such as sodium acetylide or potassium tbutoxide and the like in an organic inert solvent such as benzene, xylene, or toluene. Alternatively, compounds of the general Formula E can be prepared by hydrolysis of ketals of the general Formula D under mild conditions such as acetic acid in water at ambient temperatures.

Reduction of compounds of the general Formula E with specific reducing agents such as lithium aluminum tri-tertiarybutoxyhydride and the like then give compounds of the general Formula F. The corresponding 3,21-diacyl derivative may be prepared by acylation under various conditions including reaction of an acid anhydride such as acetic anhydride in the presence of an anhydrous organic base such as pyridine.

The following examples are illustrative of the invention, all temperatures being in degrees centigrade, unless otherwise stated:

EXAMPLE 1 9a-fiuoro-1 113,160,17a,2l-tetrahydroxypregn-5-ene-3,20- dione 16,17-acetonide A solution of 100 mg. of 3,3-bisethylenedioxy-9-ufluoro 11fi,16u,17a,21-tetrahydroxypregn-S-en-ZO-one in 10 ml. of acetic acid is left at room temperature for 15 hours then diluted with water and extracted with chloroform. The chloroform extract is washed Well with water and evaporated under reduced pressure. Crystallization of the residue gives 9a-fi110I0-1 lfi,l6a,17oc,Z1-t6tl'ahydroxypregn-S-ene-3,20-dione 16,17-acetonide.

EXAMPLE 2 9a-fiuoro-3/3,1113,16a,17a,21-pentahydroxypregn-5-en-20- one 16,17-acetonide To a solution of mg. of 9a-fluoro-1 1fi,160t,17a,21- tetrahydroxypregn-S-ene-3,20-dione 16,17-acetonide in 10 ml. of tetrahydrofuran freshly distilled from lithium aluminum hydride are added 200 mg. of lithium aluminum tri-tertiarybutoxyhydride and the mixture stirred at room temperature for 16 hours. It is then treated with a few m1. of saturated ammonium sulfate diluted with water and extracted with methylene chloride. The methylene chloride is washed well with water and evaporated under reduced pressure. Crystallization of the residue gives 9a fluoro 3I3,11;3,16oz,17u,Z1 pentahydroxypregn-S-en-ZO-one 16,17-acetonide.

Similarly, reduction of 9a-fluoro-21-(Z-tetrahydropyranyloxy) 113,161,170; trihydroxypregn 1,5 diene- 3,20-dione 16,17-acetonide and 9a-fiuoro-21-(2-tetrahydropyranyloxy) 11B,16oz,17o4 trihydroxypregn 5 ene- 3,20-dione 16,17-acetonide give the corresponding 3B-hydroxyl derivatives.

EXAMPLE 3 9a fluoro 3/3,1l 3,l6cz,17a,21 pentahydroxypregn 4- en-20-one 16,17-acet0nide and 9ot-flUOI'O-3fl,11fl,l6oz, 17,21 pentahydroxypregn 1,44iien 20 one 16,17- acetonide Following the procedure of Example 2, but substituting 90: fluoro 11fi,16a,170 ,21 tetrahydroxypregn 4- ene-3,20-dione 16,17-acetonide and 9a-fil1OIO-l lfi,l6oc, 17a,2l-tetrahydroxypregna 1,4 diene 3,20-dione 16,17- acetonide for '90: fluoro 11B,16u,17a,21 tetrahydroxypregn-5-ene-3,20-dione 16,17-acetonide, the titled compounds are obtained.

5 EXAMPLE 4 9u-fluoro-21-(Z-tetrahydropyranyloxy)-11 6,160,

hydroxypregna-1,5-diene-3,20-dione 16,17-acetonide and 9a-fluoro-2l- (Z-tetrahydropyranyloxy) -1 153160;, 17 a-trihydrOXypregn-S-ene-3,20-dione 16, 17 -acetonide To a solution of 1.0 g. of 9ot-fiuoro-21-(2-tetrahydropyranyloxy) -1 13,1 60:, 17a-trihydroxyprdgn-1,4-diene-3 ,20- dione 16,17-acetonide in 20 ml. of dimethylsulfoxide is added 9 ml. of a suspension of approximately 20% sodium acetylide in xylene. The reaction mixture is stirred at room temperature for 30 minutes and then poured slowly into 300 ml. of ice water and extracted with methylene chloride. The methylene chloride is washed well with water and evaporated under reduced pressure. Crystallization of the mother liquor gives 90:- fiuoro-21-(2-tetrahydropyranyloxy) 11,8,16a,17u-trihydroxypregna-l,5-diene-3,20-dione 16,17-acetonide.

Similarly, by starting with 9u-fluoro-21-(Z-tetrahydropyranyloxy)-11,8,16u,17u-trihydroxypregn 4 ene 3,20- dione 16,17-acetonide, there is obtained 9oc-fluOr0-21-(2- tetrahydropyranyloxy)-1l/8,16a,17a trihydroxypregn 5- ene-3,20-dione 16,17-acetonide.

By a similar procedure but substituting 1.0 g. of solid potassium t-butoxide for the sodium acetylide in xylene, the titled compounds are obtained.

EXAMPLE 5 9a-fiuoro-l1,8,16a,17u,21-tetrahydroxy-pregn-5-ene- 3,20-dione 16,17-acetonide 21-acetate A solution of 100 mg. of 9afill01'O-11,B,l6oc,l7u,2ltetrahydroxypregn-5-ene-3,20-dione 16,17-acetonide in 10 ml. of pyridine and 5 ml. of acetic anhydride is kept at room temperature for 16 hours. It is then diluted with ice water and extracted with chloroform. The chloroform is washed with water, then successively 'with 2 N hydrochloric acid, 5% sodium bicarbonate and water and evaporated under reduced pressure. Crystallization of the residue gives 9a-fluoro-11B,l6a,17a,2l-tetrahydroxypregn- 5-ene-3,20-dione 16,17-acetonide 21-acetate.

Similarly, from the title compounds of Examples 2 and 3, the corresponding 3,21-diacetates are prepared.

The invention may be variously otherwise embodied within the scope of the appended claims.

What is claimed is:

1. A compound having the formula 6 wherein R is hydrogen or acyl; R is hydrogen or acyl; R is hydrogen, acyl or 2-tetrahydropyranyl; the acyl in each instance being a hydrocarbon carboxylic acid of less than twelve carbons; R is hydroxy or acyloxy, R is hydrogen and R and R together are 0x0 (0:); X is halogen; P is hydrogen, lower alkyl, halo lower alkyl, carboxy lower alkyl or a salt or ester thereof, monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl, and Q is lower alkyl, halo lower alkyl, carboxy lower alkyl or a salt or ester thereof, monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl, or together with the carbon atom to which they are joined P and Q are cycloalkyl or monocyclic heterocyclic; and Z indicates a single or a double bond.

2. A compound in accordance with claim 1 having the name 9u-fiuoro-3 [3,1 1,6,16a,17a,2l-pentahydroxypregn-4- en-20-one 16,17-acetonide.

3. A compound in accordance with claim 1 having the name 9u-fluoro-3 [3,1 1B,16a,1711-21-pentahydroxypregn-4 4-dien-20-one 16,17-acetonide.

4. A compound in accordance with claim 1 having the name 9a-fluoro-1113,l6a,17a,21-tetrahydroxypregn-S-ene- 3,20-dione 16,17 acetonide.

5. A compound in accordance with claim 1 having the name 9oc-fl1101'O-3 5,1 1 1,160, 17 (1,21-pentahydroxypregn-5- en-20-one 16,17-acetonide.

6. A compound in accordance with claim 1 having the name 9u-fluoro-2 1,(Z-tetrahydropyranyloxy)-3B,1 1B,16u, 17u-tetrahydroxypregn-1,S-diene-ZO-one 16,17-acetonide.

7. A compound in accordance with claim 1 having the name 9oc-flL1OIO-Z1- (Z-tetrahydropyranyloxy) -3 5,1 1,8,1605, 17 a-tetrahydroXy regn-S -ene-20-one 16,17-acetonide.

8. A compound in accordance with claim 1 having the name 9u-fluoro-3 5,1 15,160 17a-pentahydroxypregn-5-en- 20-one 16,17 acetonide-3,21-diacetate.

9. A compound in accordance with claim 1 having the name 9oc-fll10I0-3 5,1 1/3,16a,17a,21-pentahydroxypregn-4- en-ZO-one 16,17-acetonide-3,2l-diacetate.

10. A compound in accordance with claim 1 having the name 9u-fiuoro-3B,11,8,16a,17a,21-pentahydroxypregn-1, 4-dien-20-one-one 16,17-acetonide-3,2l-diacetate.

References Cited UNITED STATES PATENTS 3,097,199 7/1963 Bowers 260-23955 3,173,914 3/1965 Bowers 260-239.55 3,197,469 7/1965 Fried 260239.55 3,210,340 10/ 1965 Bowers, et a1, 260239.55

OTHER REFERENCES Deghenghi et al.: Jour. Med. Chem., July 1966, pp.

LEWIS GOTTS, Primary Examiner E. G. LOVE, Assistant Examiner U.S. Cl. X.R. 42424l mg UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3 541 5Q2 Dated November 17, 1970 It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

[Column 1, third formula should read Column 2, line 46, "O. 1" should read-0.0l- Column 4, line 2 "9-cx" should read-9d- Column 5, first formula I should read 2 R 0 R 0 Column 6, line 23, "pentahydroxypregn-4" should readpenta hydroxypregn-l,; and on line 48, "20-one-one" should read-- 20-one--.

SIGN 3ND SEALED mu. "Am

ward M. mm, 1-. 2- Sam, Attesting Offioer cmimmr f Patent 

